Analyst Upgrades

• BP (BP) to buy from hold at RBS.
• Symantec (SYMC) to buy from hold at Deutsche Bank.
• GenOn Energy (GEN) and Nationwide Health Properties (NHP) to buy from hold at Citigroup.
• Logitech (LOGI) and Patriot Coal (PCX) to neutral from sell, as well as ARM Holdings (ARMH) to buy from neutral, at Goldman.
• Silvercorp Metals (SVM) to outperform from market perform at BMO Capital.
• Cinemark (CNK) to equal weight from underweight at Morgan Stanley.
• Smith & Nephew (SNN) to market perform from underperform at Bernstein.
• Molex (MOLX) to overweight from underweight at JPMorgan.

Analyst Upgrades

• Sapient (SAPE) to outperform from market perform at Wells Fargo.
• Kroger (KR) to buy from neutral at UBS.
• Harman (HAR) to overweight from neutral and Deutsche Bank (DB) to neutral from underweight at JPMorgan.
• Savient (SVNT) to outperform from market perform at JMP Securities.
• LabCorp (LH) to buy from hold at Deutsche Bank.
• Optimer Pharm (OPTR) and Landstar System (LSTR) to outperform from neutral at RW Baird.
• Essex Property Trust (ESS) to buy from neutral at Janney Capital.
• Tyson Foods (TSN) to neutral from sell at Goldman.
• Host Hotels (HST) to outperform from sector perform at RBC Capital.
• SPX Corp. (SPW) to outperform from market perform at FBR Capital.

LabCorp (LH - option chain) stock is trading lower today after the company announced that it has agreed to purchase Genzyme's (GENZ) Genzyme Genetics unit in a $925 million all-cash deal. The price was higher than some analysts expected and is expected to negatively impact LH's earnings by 0.25 over the next year, which is sending LH stock lower today. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on LH.

This morning, LH opened at $75.55 So far today the stock has hit a high of $75.99 and a low of $73.93. As of 12:25, LH is trading at $73.73 down $2.93 (-2.9%). The chart for LH looks bullish and S&P gives LH a positive 4 STARS (out of 5) buy ranking.

Option traders appear to be setting up for a bullish move on Cypress Bioscience, Inc. (CYPB). Traders plowed into 1,305 new call option contracts -- 19.19 times the average volume -- on the stock on Friday. And we know that traders were eager to get into this trade because 100% of the trades came in on the ask price.

Cypress has been in a downtrend since hitting a high around $10.00 in July 2009. The stock closed Friday at $3.39, down 10.79% during the past month.

"There are also people who avoid the doctor's office, not because they're afraid of needles, but because they can't afford it," says growth stock specialist Marc Lichtenfeld.

The contributing editor to Investment U explains, "However, times are changing. The new health care bill will enable millions more people to get their various conditions checked out. As a result, the diagnostics industry should boom.

Analyst Upgrades

• Kaufman Bros. upgraded Baidu (BIDU) to buy from hold and raised its target price for shares to $690 from $540 after Google (GOOG) said it has stopped censoring its search services on Google.cn in China. The firm believes the Chinese government is likely to restrict access to Google's site now, a move that would benefit Baidu.
• Baird upgraded Autoliv (ALV) to outperform from neutral and raised its target to $60 from $47. The firm cites valuation and strong revenue performance for the upgrade.
• Jesup & Lamont upgraded Tiffany (TIF) to buy from hold following the company's Q4 results and better-than-expected guidance. The firm has a $55 price target for shares.
• Automatic Data Processing (ADP) was upgraded to neutral from underperform at Cowen.
• American Superconductor (AMSC) was upgraded to buy from hold at Jefferies.
• Saks (SKS) was upgraded to overweight from neutral at JPMorgan.

Analyst upgrades:

• Credit Suisse upgraded Motorola (NYSE: MOT) to Outperform from Neutral after the close Monday. The firm believes Motorola's devices segment will approach breakeven in 2010 while operating margins in nonhandset segments will expand, and that a break-up story will reemerge. Credit Suisse raised its target on shares to $9.50 from $7.
• UBS upgraded BHP Billiton (NYSE: BHP) to Buy from Neutral. The firm cites BHP's leverage to iron ore, coking coal, copper, and oil for its upgrade after raising its commodity price forecasts.
• Merriman upgraded Walter Energy (NYSE: WLT) to Buy from Neutral to reflect higher met coal price forecasts. The firm believes Chinese demand is strong and has a target range of $66-$72 on the stock.
• Intersil (NASDAQ: ISIL) was upgraded to Outperform from Perform at Oppenheimer.
• Coach (NYSE: COH) was upgraded to Buy from Neutral at BofA/Merrill.
• Lockheed Martin (NYSE: LMT) was upgraded to Buy from Hold at Citigroup.

Analyst Upgrades

• Citigroup upgraded Deutsche Bank (NYSE: DB) to Hold from Sell citing reduced legacy risks and strength in the fixed income franchise.
• Janney Montgomery upgraded Fuel Systems (NASDAQ: FSYS) to Buy from Neutral based on valuation, the OEM market in Europe for alternative transportation is growing faster than expected, and the $30M equity raise was smaller than expected.
• Freeport McMoRan (NYSE: FCX) was upgraded to Outperform from Market Perform by FBR Capital. The firm believes that the company will benefit from copper supply issues over the long term, and it thinks the stock has reached an attractive entry point.
• Black & Decker (NYSE: BDK) was upgraded to Neutral from Underperform at Credit Suisse.
• American Tower (NYSE: AMT) was raised to Overweight from Neutral at JPMorgan.
• EMC Corp. (NYSE: EMC) was upgraded at Barclays to Overweight from Equal Weight.

Analyst upgrades:

• Deutsche Bank upgraded AmerisourceBergen (NYSE:ABC) to Buy from Hold on valuation as it views the risk/reward as favorable at current levels. Deutsche raised its target price to $41.50 from $38.
  
• FBR Capigal upgraded Charlotte Russe (NASDAQ:CHIC) to Outperform from Market Perform following the company's Q2 results on expectations merchandise improvements and cost-cutting efforts will drive continued margin expansion. The firm raised its target on shares to $15 from $10.
  
• Oppenheimer upgraded Fidelity National (NYS:FIS) to Outperform from Perform as it believes the Metavante (MV) acquisition makes strategic sense and the stock's risk/reward is favorable. The firm's target price is $25.
• First American (NYSE:FAF) was upgraded to Outperform from Market Perform at Keefe Bruyette.
  
• Nokia (NYSE:NOK) was raised to Neutral from Underweight at JP Morgan.
  
• Parker-Hannifin NYSE:(PH) was lifted at Wachovia to Outperform from Market Perform.

MOST NOTEWORTHY: AeroVironment, American Oriental and Intel were today's noteworthy initiations:

• Suntrust initiated AeroVironment (NASDAQ: AVAV) with a Buy rating and $32 target and expects AVAV's market leadership in unmanned aerial systems and increased effort in the high altitude to drive strong organic growth.
• Jefferies believes American Oriental (NYSE: AOB) is capable of making sizable acquisitions given its strong cash position and finds the valuation attractive at current levels. The firm started shares with a Buy rating and $20 target.
• Intel (NASDAQ: INTC) was initiated with a Neutral rating and $30 target at Baird on valuation.

OTHER INITIATIONS:

• Equinix (NASDAQ: EQIX) was initiated with a Market Perform rating at Wachovia.
• Goldman started Quest Diagnostics (NASDAQ: DGX) with a Sell rating and $55 target, LabCorp (NASDAQ: LH) with a Neutral rating and $77 target and Pinnacle Entertainment (NASDAQ: PNK) with a Buy rating and $35 target.

MOST NOTEWORTHY: Gen-Probe, Monster Worldwide, LabCorp and Quest Diagnostics were today's noteworthy initiations:

• Deutsche Bank initiated shares of Gen-Probe (NASDAQ: GPRO) with a Buy rating and $78 target and expects the company's broad product portfolio in Clinical Diagnostics and Blood Screening to drive growth.
  
• CIBC initiated Monster Worldwide (NASDAQ: MNST) with a Sector Performer rating, as they believe their macro concerns are more important than the company's intermediate-term prospects and its position within the global recruiting market.
  
• William Blair views the valuation of LabCorp (NYSE: LH) as compelling given the company's growth outlook. The firm started shares off with an Outperform rating.
  
• William Blair also initiated Quest Diagnostics (NYSE: DGX) with a Market Perform rating, and prefers a wait-and-see approach as the company's diversification strategy unfolds.

OTHER INITIATIONS:

• Wachovia initiated Cleco (NYSE: CNL), ITC Holdings (NYSE: ITC) and Aqua America (NYSE: WTR) with Outperform ratings and American States Water (NYSE: AWR) with a Market Perform rating.
  
• Baird resumed coverage of Ritchie Bros (NYSE: RBA) with a Neutral rating and $78 target.

It's not a glamorous business, but it's a necessary (and evidently a profitable) one. Laboratory Corp. of America Holdings (NYSE: LH) earned an unlikely distinction as the top performer in 2000 among our basket of hundreds of stocks. The company provides mostly routine laboratory and testing services, analyzing close to 400,000 specimens each day.

1999 was a very good year for the market and for our faux portfolio, with Qualcomm (NASDAQ: QCOM) shares leaping almost 2600% to turn just over $6,500 into more than $175,000. With $175,327 at his disposal, our happy investor scooped up 19,016 shares of LH, trading at $9.22 at the beginning of the 'aughts. Though the market proceeded to tumble, with the tech bubble showing signs of initial weakness as early as March, LabCorp. shares continued higher for the entire year. In fact, the stock peaked on December 28, 2000, before embarking upon a months-long pullback.



By the end of 2000, hanging chads made for a very interesting election outcome and LH shares had gained a total of 377%, closing the year at $44. Our hypothetical hindsight portfolio was now worth $836,704. After four years of absolutely brilliant (read: highly improbable) stock picking, we were closing in on the million-dollar mark.

Next: Step 5: NVIDIA (NVDA), 2001

Beth Gaston Moon is an analyst at Schaeffer's Investment Research.

MOST NOTEWORTHY: Taser Int'l (TASR), Motorola (MOT), Advantest (ATE), STMicroelectronics (STM) and Joy Global (JOYG) were today's noteworthy upgrades:

• Merriman upgraded shares of Taser Int'l (NASDAQ: TASR) to Buy from Hold on valuation following the 25% decline in price since late July, accelerating law enforcement demand and upside potential from the recently launched personal TASER C2.

• Lehman upgraded shares of Motorola (NYSE: MOT) to Overweight from Equal Weight as they believe increased production and opex progress in Q3 could signal a turnaround at the company's phone unit.

• Jefferies upgraded Advantest (NYSE: ATE) to Hold from Underperform on valuation.

• STMicroelectronics (NYSE: STM) was upgraded to Market Perform from Underperform on valuation at Bernstein.

• Stifel upgraded shares of Joy Global (NASDAQ: JOYG) to Buy from Hold following the in line Q3 report as they believe bad news is reflected in valuation...

OTHER UPGRADES:

• Idacorp (NYSE: IDA) was upgraded to Market Perform from Under Perform at Wachovia.

• UBS upgraded TDK Corp (NYSE: TDK) to Neutral from Sell.

• Wedbush raised Big Lots (NYSE: BIG) to Buy from Hold, with a $35 target, and DSW Inc. (NYSE: DSW) to Hold from Sell, with a $29 target.

• LabCorp (NYSE: LH) was upgraded to Outperform from Neutral at Cowen.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

MOST NOTEWORTHY: Old Dominion Freight (ODFL), Jamba (JMBA), AMD (AMD), Orbitz Worldwide (OWW) and Quest Diagnostics (DGX) were today's notable initiations:

• Baird is positive on Old Dominion's (NASDAQ: ODFL) growth opportunities, valuation, 2008 improving truck fundamentals, and a potentially seasonally stronger Q4, starting shares with an Overweight rating and $36 target.

• Merriman initiated Jamba (NASDAQ: JMBA) with a Buy rating, as the company aggressively expands its store base beyond California.

• BMO Capital believes AMD (NYSE: AMD) may lose the Intel platform integrated graphics market, and sizeable Intel platform discrete graphics market share. The firm initiated AMD shares with an Underperform rating and $10 target.

• Soleil has concerns regarding Orbitz Worldwide's (NYSE: OWW) decelerating growth and poorer business mix vs. competitors and started shares with a Hold rating and $13 target.

• Credit Suisse initiated Quest Diagnostics (NYSE: DGX) with a Neutral rating and $61 target, citing the recent UnitedHealth (UNH) contract loss, slowing growth, and valuation for its Neutral rating...

OTHER INITIATIONS:

• McDermott (NYSE: MDR) and Capella Education (NASDAQ: CPLA) were initiated with Buy ratings at Citigroup.

• JMP Securities started ShoreTel (NASDAQ: SHOR) with a Market Outperform rating.

• Credit Suisse initiated LabCorp (NYSE: LH) with an Outperform rating.

• FTN Midwest started Northwest Airlines (NYSE: NWA) with a Buy rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Looks like we still might have a summer swoon, and if we do, then many of the stocks on your watch list might pop up as buy opportunities. One more stock you might want to add to that list is Quest Diagnostics Inc. (NYSE: DGX), the world's leading clinical lab. It operates 2,000 patient services centers where samples are collected, along with about 30 primary labs and 150 rapid response labs throughout the US and in Mexico and the UK.

Investment ideas come from many different avenues. This one came to me because I donated blood this week. Not everyone is eligible to donate and only 5% of that group actually do. Our whole blood supply is supported by very few people. I started thinking about the cost of collecting, maintaining and distributing the blood and how quality control is done. According to the PBS series Red Gold: The Epic Story of Blood: "Currently, the average base price of a unit of RBCs [red blood cells] is in the range of $100-$160, but will increase as more sophisticated testing for transmissible diseases (e.g., HIV and viral hepatitis) are introduced." The news of globe-trotting tuberculosis patient Andrew Speaker also brought the the idea of labs and screening to mind.

Quest runs many different tests and screens for many different things. Ironically, now I'm screening the (blood) screener, and it did not take long to discover there was some value here. You can see some of my often repeated criteria; low P/S, fair P/B, pays a dividend (wish it was higher), not much debt, good cash-flow, and ROE is solid and higher than the P/E.

• Price-to-earnings P/E: 17.69 (TTM)
• Price-to-sales P/S: 1.55 (TTM)
• Price-to-book P/B: 3.13 (TTM)
• Price-to-cash-flow P/CF: 9.95 (TTM)
• Return-on-equity ROE: 20.2 (TTM)
• Long Term Debt-to-Equity (MRQ) 0.5
• Dividend Yield 0.82%

Quest has been building shareholder value for quite some time and the stock price is nearing a two year low, and 20%+ below its all time high set last year.